Research Fields

1. The pathogenesis of ovarian/fallopian tube tumors

2. Ovarian cancer drug resistance reversal

3. Cervical disease screening strategy

4. Standardized treatment of endometrial cancer

5. Environmental endocrine disruptors and gynecological diseases

6. Female pelvic floor related diseases

7. Female sexual health

Honor Reward

Patent:

Shen Yang, Wu Yongping, Ren Mulan, et al. A method for the synthesis of taxol compounds coupled with octreotide .

Acadamic Activity:

2007-present: Member of Gynecologic Oncology Branch, Cancer Institute of Jiangsu Province, China

2013-present: Younth member of Obstetrics and Gynecology Branch, WM Committee of JiangsuProvince

2013-present: Younth member of Obstetrics and Gynecology Bran


Academic Achievements

Selected Publications

1. Shen Y, Hu YL, Zhang Y. Effects of Danshensu on maternal syndrome in phosphatidylserine/phosphatidylcholine microvesicle induced-mouse model: is it a candidate for preeclampsia remedy? Chin Med J (Engl),2010;123(7):895-900

2. Shen Y, Hu YL, Zhang Y. Favorable Maternal and Fetal Effects of Danshensu in an Experimental Mice Model of Preeclampsia. Hypertens Pregnancy, 2011,30:465-480

3. Shen Y, Ren ML, Shi YH, Zhang YX, Cai YL. Octreotide enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy in vitro. Exp Ther Med, 2011,2(6):1171-1176

4. Shen Y, Ren ML, Shi YH, Zhang YX, Cai YL. Octreotide is the favorable alternative for cisplatin resistance reversal of ovarian cancer in vitro and in nude mice in vivo. Eur J Gynecol Oncol, 2012,33(6) :584-590

5. Shen Y, Xu Q, Ren M, et al. Measurement of Phenolic Environmental Estrogens in Women with Uterine Leiomyoma. PLoS ONE. 2013,8(11):e79838.

6. Shen Y, Xu Q, Xu J, Ren ML, Cai YL. Environmental exposure and risk of uterine leiomyoma: an epidemiologic survey. Eur Rev Med Pharmacol Sci.2013 ;17(23):3249-3256.

7. Shen Y, Xu Q, Ren ML, Cai YL, Xu J. Role of single nucleotide polymorphisms in estrogen-metabolizing enzymes and susceptibility to uterine leiomyoma in Han Chinese: A case–control study. J Obstet Gynaecol Res, 2014,40(4):1077-1084

8. Shen Y, Ren ML, Xu J, Xu Q, Ding YQ, Wu ZC, Zhang HB, Huang XX, Cai YL. A Multicenter Case-Control Study on Screening of Single Nucleotide Polymorphisms in Estrogen-Metabolizing Enzymes and Susceptibility to Uterine Leiomyoma in Han Chinese. Gynecol Obstet Invest. 2014;77(4):224-30.

9. Shen Y, Ren ML, Feng X, Cai YL, Gao YX, Xu Q. An evidence in vitro for the influence of bisphenol A on uterine leiomyoma. Eur J Obstet Gynecol Reprod Biol. 2014 Jul;178:80-3

10.Shen Y, Ren ML, Feng X, Gao Yongxing, Xu Q, Cai YL. Does nonylphenol promote the growth of uterine fibroids? Eur J Obstet Gynecol Reprod Biol. 2014 Jul;178:134-7

11.Zhou FQ, Zhang L, Liu A, Shen Y, et al. Measurement of phenolic environmental estrogens in human urine samples by HPLC–MS/MS and primary discussion the possible linkage with uterine leiomyoma. J Chromatogr B, 2013;938:80-85.

12.Shen Y, Wu Y, Lu Q, Zhang P, Ren M. Transforminggrowth factor-β signaling pathway cross talking with ERα signaling pathway onregulating the growth of uterine leiomyoma activated by phenolic environmentalestrogens in vitro. TumourBiol. 2015 Jul 30. [Epub ahead of print]

13.Yang Shen,Yanting Wu,Qing Lu,Mulan Ren. Vegetarian diet and reduced uterine fibroids risk: A case–control study in Nanjing, China.Journal of obstetrics and gynaecology research.2016,42(1):87-94.

14.Yang Shen, Yi-Min Dong, Qing Lu, Jie Xu,Yan-Ting Wu, Seong Seok Yun,Mu Lan Ren. Phenolic environmental estrogens in urine and blood plasma from women with uterine leiomyoma: Epidemiological survey.Journal of obstetrics and gynaecology research.2016,42(4):440-445.

15.Yang Shen.Mid-urethral sling approach for female stress urinary incontinence:benefits versus risks. American Journal of Clinical and Envrionmental Obestetrics and Gynecology.2015,2(4):151-165 .

16.Lili Fan, Yang Shen, Chen Xi, Mulan Ren.Molecular Targeted Drug Therapy of Ovarian Cancer.ARC Journal of Gynecology and Obstetrics.2016,1(1):1-7 .

17.Yun S, Vincelette ND, Segar JM, Dong Y, Shen Y, Kim DW, Abraham I.Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.Clin Lymphoma Myeloma Leuk.2016 ,16(6):e85-94.

18.Yang Shen,Xiao-Yu Zhang,Xi Chen,Li-Li Fan,Mu-Lan Ren,Yong-Ping Wu,Kenneth Chanda,Shi-Wen Jiang.

Synthetic paclitaxel-octreotide conjugate reverses the resistance of paclitaxel in A2780/Taxol ovarian cancer cell line.Oncology reports.


2016,37(1):219-226.

19.Xi Chen, Xiao-Yu Zhang, Yang Shen, Li-Li Fan, Mu-Lan Ren, Yong-Ping Wu.Synthetic paclitaxel octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice.Oncotarget.2016,7(50), 83451-83561.

20.Shen Y , Zhang XY , Chen X , Ren ML , Cai YL.Octreotide reverses the resistance of A2780/Pacliaxel ovarian cancer cell line to paclitaxel chemotherapy in vitro.J Cancer Res Ther.2016, 12 (2):657-62.

21.Shen Y, Zhang XY, Chen X, Fan LL, Ren ML, Wu YP, Chanda K, Jiang SW. Syntheticpaclitaxel-octreotide conjugate reverses the resistance of paclitaxel inA2780/Taxol ovarian cancer cell line[J]. Oncology Reports, 2017, 37(1):219-226

22.Duan P, FanL, Gao Q, Silwal BMRenM, Shen Y, Qu W. Targeted Therapy of Ovarian Cancer with AngiogenesisInhibitors[J]. Current Drug Targets, 2017, 18(10):1171.

23.Qian QP, Zhang X, Ding B, Jiang SW, Li ZM, Ren ML, et al. Performance of P16/Ki67dual staining in triaging hr-HPV-positive population during cervical Cancerscreening in the younger women. 2018.

24.Shen Y, Lu Q, Zhang P, Wu Y, RenM. The effect of TGF-β signaling on regulating proliferation of uterine leiomyomacell via ERα signaling activated by bisphenol A, octylphenol and nonylphenol invitro. 2018.